Comments
JB Chemicals & Pharmaceuticals Ltd has slashed the price of a drug Azmarda, used in patients who suffered heart failure, by about 50 per cent.
“Azmarda, which contains the patented molecule Saccubutril-Valsartan, is indicated for heart failure. After the price reduction, Azmarda 50 mg will cost about ₹39.60 per tablet as compared to the present price level of ₹78 per tablet,” a company statement said on Thursday.
“This move will significantly reduce the overall monthly treatment cost from ₹4,500 to ₹2,200,” Dilip Singh Rathore, President (Domestic Business) of JB Pharma, said.
To go off-patent
The molecule is expected to go off-patent in January 2023. In April 2022, JB Pharma acquired the Azmarda brand from Novartis AG, Switzerland, for the India region for a consideration of ₹246 crore.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.